Compare Amgen, Inc. (AMGN) vs ARK Next Generation Internet ETF (ARKW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ARK Next Generation Internet ETF — how do they compare? Amgen, Inc. trades at $417.55 (market cap $224.14B), while ARK Next Generation Internet ETF trades at $149.88. The key difference: Amgen, Inc. pays a 2.43% dividend while ARK Next Generation Internet ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | ARKW | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $182.20 |
52-Week Low | $271.18 | $114.45 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
ARKW trades at $150.88, up 0.87% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The ETF focuses on next-generation internet companies, though key financial ratios are not disclosed in the provided data. Recent news highlights long-term growth potential in AI and cloud infrastructure, balanced by near-term capital spending headwinds.
The outlook is mixed, with strong technical momentum but fundamental metrics unavailable for valuation. Risks include market skepticism on AI investments and sector volatility. Analyst sentiment is cautious, citing near-term challenges despite long-term positioning in transformative technologies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →
